A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 1
2022-06-27
عنوان الدراسة
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 1
داعم الدراسة
Eli Lilly
دواء الدراسة
Mirikizumab
رقم بروتوكول الدراسة
I6T-MC-AMAN
حالة الدراسة
Ongoing
موقع الدراسة
KFSH-D
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。